Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST) Meeting Abstract
| Authors: | Kieran, M. W.; Hargrave, D. R.; Cohen, K. J.; Aerts, I.; Dunkel, I. J.; Hummel, T. R.; Jimenez, I.; Pearson, A. D. J.; Pratilas, C. A.; Whitlock, J.; Bouffet, E.; Shen, W. P. V.; Broniscer, A.; Bertozzi, A. I.; Sandberg, J. L.; Florance, A. M.; Suttle, B. B.; Haney, P.; Russo, M. W.; Geoerger, B. |
| Abstract Title: | Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900007 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.10004 |
| Notes: | Meeting Abstract: 10004 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
